How to buy Editas Medicine (EDIT) stock
Editas Medicine, whose ticker is EDIT, is a leading gene-editing company that continues to thrive in 2022. Investing in Editas Medicine shares seems to be the right option for people who are searching for medium-term and long-term returns.
How to buy Editas Medicine stock with a Brokerage Account
Investing in stock is a great way to ensure the money you earn is kept safe until you need it and grow your rich. If you are interested in investing in Editas Medicine, the most straightforward way is to buy shares of the company through a brokerage account.
The majority of online stock brokers have eliminated trading commissions, so most (but not all) are on a level playing field as far as costs are concerned. However, some brokers offer customers a variety of educational tools, access to investment research, and other features that are especially useful for newer investors. Others offer the ability to trade on foreign stock exchanges. Some have physical branch networks, which can be nice if you want face-to-face investment guidance. And many will let you try a demo version before committing any money.
The best brokerage for beginners charge no commissions for online stock and ETF trades, such as E*Trade, Robinhood and eToro.
Should you buy Editas Medicine stock?
Investing in companies with poor financial strength have a higher risk of permanent loss. If you do decide to invest in Editas Medicine, make sure you should always take the time to research EDIT stock fully before investing your money, especially if you haven’t bought shares before. The more knowledge you have, the better your chances of making a wise investment.
Is Editas Medicine stock a buy right now?
Based on 10 analysts offering recommendations for EDIT, there are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock. Their average price target is $31.64 — over 89% above the current price ($16.72).
